Slide 1: H1 FY25 Investor Presentation
H1 FY25 Investor Presentation 27 February 2025 Mach7 Technologies | ASX: M7T
Slide 2: Mach7 Technologies develops innovative image management and viewing solutions
Mach7 Technologies develops innovative image management and viewing solutions that form the core of an integrated enterprise imaging ecosystem.
Slide 3: Agenda
Agenda 1 Business Overview Mike Lampron | CEO 2 H1 FY25 Results Dyan O’Herne | CFO 3 Outlook Unless otherwise stated, all dollar values are in Australian dollars (AUD) 3
Slide 4: Business Overview
as “q Ss Business Sienre = Mech? Te
Slide 5: Our Business
Our Business Our Purpose Our Offering To enable exceptional Innovative data patient care by storage, management empowering and image viewing healthcare providers solutions for the to make more healthcare enterprise. informed decisions. 5
Slide 6: Our Value Proposition
Our Value Proposition Global Company with a Personal Touch Lasting Technology Built for the Entire Enterprise A future-proof solution built on a modern A software-only solution designed for the whole technology stack that allows customers to grow, healthcare organisation. adapt and innovate. Persona
Slide 7: Our Solution: Enterprise Imaging Platform
Our Solution: Enterprise Imaging Platform Enterprise Enterprise Workflow Data Management Diagnostic Viewing Orchestration Vendor Neutral Archive eUnity Enterprise Diagnostic Viewer Communication Workflow Engine ✓ Consolidate ALL images across the enterprise ✓ Zero footprint HTML-5 viewer; 100% fidel
Slide 8: Our Strategic Priorities
Our Strategic Priorities Leverage strategic pillars to drive next phase of growth Cloud Service and Integration and Enablement Supportability Interoperability Leverage cloud-based APIs and Utilise proven, industry-standard Continue expanding our independent, storage models to provide applications an
Slide 9: Our Innovation: UnityVue
Our Innovation: UnityVue A next-generation radiology reading solution UnityVue is a transformative overlay or alternative to legacy PACS systems. Its unified worklist and viewer deliver essential tools and information, enhancing radiologists’ efficiency and well-being, through its intuitive, stress-
Slide 10: Our Progress Against Strategy
Our Progress Against Strategy Strengthening business and competitive positioning Team Customers Product Realign sales team to focus Focus on net new logos and Leverage investment in on net new sales and conversion of a large and product innovation to customer success diverse pipeline of demonstrate
Slide 11: H1 FY25 Results
hes ‘. x * = ' \ a ‘i ‘ \ ae ‘ * ‘> % % ¥ i & on & * -, ~ TIMACH7 H1 FY25 Results
Slide 12: H1 FY25 in Review
H1 FY25 in Review Positioning Mach7 for long-term growth 1 Delivered strong growth in CARR, ARR and revenue Achieved positive EBITDA and NPATA as strong revenue growth and cost discipline 2 drove operating leverage and further progress towards Recurring Revenue covering OPEX 58% 32% 3 Invested in pe
Slide 13: H1 FY25 Financial Highlights
H1 FY25 Financial Highlights A$17.7M A$12.6M A$31.8M A$25.1M Revenue Recurring Revenue3 CARR4 ARR5 Run Rate +A$4.4M or +33% on PCP1 +A$2.8M or +28% on PCP +A$5M or +19% on PCP +A$6.5M or +35% on PCP On track to meet FY25 71% of total revenue On track to meet FY25 ~80% of OPEX (PCP: ~65%) Guidance2 G
Slide 14: 33% Revenue Growth on PCP
33% Revenue Growth on PCP Recurring revenue up 28% on PCP High quality recurring revenue covering 80% OPEX 18 90% • Revenue of A$17.7M, up 33% on PCP (H1 FY24: 16 80% 80% 72% A$13.3M). On track to meet FY25 guidance 65% 14 65% 70% Opex % recurring revenue • Recurring Revenue of A$12.6M, up 28% on PC
Slide 15: Focused on conversion of strong pipeline
Focused on conversion of strong pipeline New contracts with existing customers demonstrate success of “land & expand” model Sales orders by half – TCV in constant currency1 • Sales orders of A$16.2M (TCV) compared to A$49.5M in H1 50 FY24 which was a large renewal period with record sales orders 45
Slide 16: Strong revenue growth and cost discipline drive positive EBITDA
Strong revenue growth and cost discipline drive positive EBITDA On track to achieve FY25 guidance for revenue and opex growth Earnings (A$M)1 H1 FY25 H1 FY24 $ Change % Change • OPEX growth of 15% includes targeted investment in three strategic pillars alongside careful cost management and Revenue 1
Slide 17: Strong financial position with no debt
Strong financial position with no debt On-market share buy-back of up to A$5M expected to commence in March 2025 • Cash on hand of A$23.6M at 31 December 2024, up 4% on 31 December 2023 (A$22.7M); A$25.3M at 29 Jan 2025. Mach7 Closing Cash Balance has no debt 25.0 • Transition to predominantly Subsc
Slide 18: Outlook
Outlook
Slide 19: Outlook
Outlook • As the healthcare landscape continues to evolve, Mach7 is perfectly aligned to compete in both acute and non-acute settings. • We have realigned our sales team to have absolute focus on net new wins along with the creation of a customer success team to concentrate on existing business “lan
Slide 20: Contact Us
Contact Us Investor Relations, Mach7 Françoise Dixon +61 (0) 412 292 977 ir@mach7t.com Registered Office: Level 4 | 100 Albert Road, South Melbourne, VIC This document was authorised for release to the ASX by Mike Lampron, Managing Director and Chief Executive Officer Mach7 Technologies
Slide 21: Disclaimer
Disclaimer “Forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date